Rare disease clinical research network's urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy

Hepatology

Volumn 57, Issue 6, 2013, Pages 2100-2102

  Mistry, Pramod K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININOSUCCINATE LYASE; BENZOIC ACID PLUS PHENYLACETIC ACID; CARBAMOYL PHOSPHATE SYNTHASE; GLYCEROL PHENYLBUTYRATE; ORNITHINE CARBAMOYLTRANSFERASE; PHENYLACETIC ACID;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FATTY ACID OXIDATION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERAMMONEMIA; MAINTENANCE THERAPY; NITROGEN METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INTAKE; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); TASTE DISORDER; TREATMENT OUTCOME; UREA CYCLE DISORDER;

AMMONIA; FEMALE; GLYCEROL; HUMANS; MALE; PHENYLBUTYRATES; UREA CYCLE DISORDERS, INBORN;

EID: 84879100574     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26106     Document Type: Article

References (9)

1. Brusilow SW, Horwich AL. Urea cycle disorders. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonrakis SE, Bellabio A, eds. The Online Metabolic and Molecular Bases of Inherited Disease. Available at: www.ommbid.com. Accessed October 22, 2012.
2. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. Pediatr Res 2009; 66: 96-101.
3. Vockley J, Vockley CM. Clinical trials: curing a critical deficiency in metabolic medicine. Mol Genet Metab 2010; 99: 244-245.
4. Cederbaum S, Lemons C, Batshaw ML. Alternative pathway or diversion therapy for urea cycle disorders now and in the future. Mol Genet Metab 2010; 100: 219-220.
5. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007; 356: 2282-2292.
6. Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, et al. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics, and ammonia control. Mol Genet Metab 2010; 100: 221-228.
7. Diaz GA, Krivitzky LS, Mokhtarani M, Rhead W, Bartley J, Feigenbaum A, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. HEPATOLOGY 2012 Sep 7. doi: 10.1002/hep.26058.
8. Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, et al. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab 2010; 100( Suppl 1): S97-105.
9. McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. HEPATOLOGY 2010; 51: 2077-2085.